Belinostat Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 100 mg/10 mL
Reference Brands: Beleodaq (USA)
Category:
Oncology Cancer Care
Belinostat is available in Injection
and strengths such as 100 mg/10 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Belinostat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Belinostat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Belinostat is a novel hydroxamic acid–type histone deacetylase (HDAC) inhibitor with potent antineoplastic activity, marketed under the brand name Beleodaq and previously known as PXD101. It is designed for the treatment of hematological malignancies, including peripheral T-cell lymphoma, as well as certain solid tumors. Belinostat works by targeting HDAC enzymes, which play a key role in regulating gene expression and cellular growth. By inhibiting these enzymes, belinostat promotes tumor cell apoptosis, induces cellular differentiation, inhibits angiogenesis, and suppresses tumor proliferation.
This agent has also shown potential in sensitizing drug-resistant tumor cells to other anticancer therapies, possibly through mechanisms involving the down-regulation of thymidylate synthase, enhancing the efficacy of combination treatments. Belinostat is administered intravenously under medical supervision and is available in precise, standardized dosing to ensure safety and effectiveness in cancer therapy. Developed by TopoTarget and commercialized as Beleodaq, belinostat represents an important option in the targeted treatment of cancers, providing clinicians with a novel mechanism of action to combat malignancies that are difficult to treat with conventional therapies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing